Compendium of Cancer Genome Aberrations

BRST5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
No edit summary
No edit summary
 
(13 intermediate revisions by 4 users not shown)
Line 42: Line 42:
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|Disease
|Disease
|Ritika Pathak
|2/25/2026
|
|
|PENDING
|
|
|
|Katherine Geiersbach
|
|
|
|
|
|
|
Line 114: Line 114:
|
|
|-
|-
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||Joanna George
|
|3/28/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 179: Line 179:
|
|
|-
|-
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||Sresi Singh (trainee), Katherine Geiersbach
|
|2/26/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 235: Line 235:
!'''Notes'''
!'''Notes'''
|-
|-
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||Vaishnavi Devarakonda
|
|2/19/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||Vaishnavi Devarakonda
|
|2/19/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||Braa Elwaleed Mohamed Ahmed (trainee) +Katherine to find mentor
|2/20/2026
|
|
|PENDING
|
|
|Katherine Geirsbach
|
|
|
|
|-
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||
|
|
|
|
|
|
|-
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||Hieu Nguyen
|9/23/2025
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 280: Line 280:
|
|
|-
|-
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||Sree Vishmaya
|
|3/20/2026
|
|
|
|
|
|
|
|Katherine Geiersbach
|
|
|
|
Line 363: Line 363:
|
|
|-
|-
|[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
|[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach;
Jun Liao
|10/12/02022
|10/12/02022
|11/11/2023
|11/11/2023
Line 372: Line 373:
|2024 template added
|2024 template added
|-
|-
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Katherine Geiersbach
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen;
Katherine Geiersbach
|10/12/2022
|10/12/2022
|11/11/2023
|11/11/2023
Line 467: Line 469:
|
|
|-
|-
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| ||
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor
|
|2/20/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde;
H. Evin Gulbahce;
 
Katherine Geiersbach
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 524: Line 529:
|
|
|-
|-
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor
|
|2/20/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 610: Line 615:
|
|
|-
|-
|[[BRST5:Nodular fasciitis|Nodular fasciitis]]||Disease||
|[[BRST5:Nodular fasciitis|Nodular fasciitis]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]||Disease||
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Desmoid fibromatosis|Desmoid fibromatosis]]||Disease||
|[[BRST5:Desmoid fibromatosis|Desmoid fibromatosis]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Katherine Geiersbach
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|8/11/2023
|N/A
|11/11/2023
|N/A
|COMPLETE
|N/A
|
|N/A
|Katherine Geiersbach
|N/A
|1/8/2025
|N/A
|2024 template
|Migrated page to STBT5.
|-
|-
|[[BRST5:Schwannoma|Schwannoma]]||Disease||
|[[BRST5:Schwannoma|Schwannoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Neurofibroma|Neurofibroma]]||Disease||
|[[BRST5:Neurofibroma|Neurofibroma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 675: Line 680:
!'''Notes'''
!'''Notes'''
|-
|-
|[[BRST5:Granular cell tumour|Granular cell tumour]]||Disease||
|[[BRST5:Granular cell tumour|Granular cell tumour]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Leiomyoma|Leiomyoma]]||Disease||
|[[BRST5:Leiomyoma|Leiomyoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Leiomyosarcoma|Leiomyosarcoma]]||Disease||
|[[BRST5:Leiomyosarcoma|Leiomyosarcoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Lipoma|Lipoma]]||Disease||
|[[BRST5:Lipoma|Lipoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Angiolipoma|Angiolipoma]]||Disease||
|[[BRST5:Angiolipoma|Angiolipoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 759: Line 764:
----
----
|-
|-
|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]||Disease||
|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Follicular lymphoma|Follicular lymphoma]]||Disease||
|[[BRST5:Follicular lymphoma|Follicular lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 788: Line 793:
!'''Notes'''
!'''Notes'''
|-
|-
|[[BRST5:Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma]]||Disease||
|[[BRST5:Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
|[[BRST5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||
|[[BRST5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 920: Line 925:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 929: Line 934:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 938: Line 943:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 947: Line 952:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 956: Line 961:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 965: Line 970:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 974: Line 979:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
Line 983: Line 988:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
Retrieved from "https://content.ccga.io/index.php/BRST5:Volunteer_Assignments_and_Opportunities"